Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Locally Advanced Pancreatic Cancer. (LAPTOP)

  • STATUS
    Recruiting
  • End date
    Feb 8, 2024
  • participants needed
    20
  • sponsor
    Herlev Hospital
Updated on 8 August 2022

Summary

Pancreatic ductal adenocarcinoma (PDAC) remains a dreadful disease due to its often advanced stage at diagnosis and poor sensitivity to chemotherapy. A locally unresectable tumor (locally advanced pancreatic cancer (LAPC)) is present in 30% of the cases and is defined as a surgically unresectable tumor encasing the adjacent arteries [celiac axis, superior mesenteric artery (SMA)]. In these patients, chemotherapy has been the standard treatment for decades, optionally combined with radiotherapy. The results of small randomized trials comparing chemoradiotherapy with chemotherapy of patients with LAPC are divergent. Considering the emerging role of the tumor microenvironment (TME), the combination of checkpoint blocking antibodies with agents that target the inhibitory effects of the TME could lead to better responses in tumor historically resistant to checkpoint blocking antibody approaches. Furthermore, the addition of standard-of-care chemotherapy could further potentiate the anti-tumor effects of immunotherapy approaches by reducing the tumor burden, exposing antigens, and directly affecting the immunosuppressive TME compartment.

To explore the safety and synergy of the proposed combinatorial approach, participants with locally advanced PC will receive nivolumab and ipilimumab administered in combination with gemcitabine and nab-paclitaxel followed by immune-chemoradiation.

Description

Patients receive nivolumab and ipilimumab. Nivolumab 3 mg/kg will be given on Day 1 (± 3 days) of each 28-day treatment cycle. Ipilimumab 1 mg/kg will be given only on day 1 in cycle

  1. Nivolumab will be administered as an IV infusion over 30 (± 5) minutes and then, after a 30 minutes rest period, ipilimumab will be administered as an IV infusion over 30 (± 5) minutes.

Pre-medication for chemotherapy (based on standard-of-care and local institutional standards) and chemotherapy will then be administered after a further 30 minutes rest period. The recommended dose of nab-paclitaxel is 100 mg/m2 administered as an IV infusion over 30 to 40 minutes on Days 1, 8, and 15 of each 28-day cycle. Gemcitabine 800 mg/m2 will be adminestered over 30 to 40 minutes immediately after nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle.

At the beginning of cycle 3, patients also undergo concurrent MRI-guided adaptive SBRT (8 Gy x 3 fractions) delivered by ViewRay MR-Linear Accelerator.

Cycles repeats every 4 weeks for 4 courses (16 weeks) in the absence of disease progression, unacceptable toxicity, withdrawal of consent, or study closure.

Once 4 cycles of study treatment have been completed, subjects without disease progression or unacceptable toxicity may continue as per Investigator's Choice to either:

  • Continuation of treatment with nivolumab, nab-paclitaxel and gemcitabine or surgery. Nivolumab can be continued until progressive disease (PD), unacceptable toxicity, withdrawal of consent, or up to 12 cycles in total. Patients will receive chemotherapy until PD, unacceptable toxicity or withdrawal of consent, according to investigator's judgment
  • If tumor response allows for surgical intervention, the subject will be eligible for that treatment as deemed appropriate by the investigators. Surgical intervention may not occur prior to completing the planned 4 cycles of nivolumab, nab-paclitaxel, gemcitabine and SBRT regardless the patient demonstrates a major response to therapy. Patients after PC resection will receive treatment until recurrence, unacceptable toxicity, withdrawal of consent, clear clinical deterioration, or for a maximum of 6 cycles, according to investigator's judgment Patients who discontinue without PD (stable disease (SD), partial response (PR), or complete response (CR)) will have both the safety follow-up period and survival follow-up period to occur simultaneously during the 2-year follow-up period. The duration of this follow-up is up to 2 years following the last dose of study treatment, although a longer follow-up period could be considered in selected cases if an efficacy signal is apparent. Patients will receive follow-up CT/MRI scans every 2 months (±14 days) until documented progression of disease, withdrawal of consent from active participation in the study, lost to follow-up, or for at least 2 years after start of treatment, whichever is earliest. Tumor evaluations will be assessed by the investigators and response to be determined according to response evaluation criteria in solid tumors (RECIST) v1.1 guidelines. Tumor assessment scans, for participants who have ongoing clinical benefit beyond the 2-year period from start of treatment, may continue to be collected as part of standard-of-care treatment. Subsequent therapies will also be recorded in this survival follow-up period.

All subjects who discontinue treatment for any reason will have a safety follow-up visit about 30, 60 and 100 days after treatment discontinuation and will be followed for OS and post-study anticancer therapies approximately every 90 days by phone or review of medical records until death, withdrawal of consent, or lost to follow-up.

To minimize the risks of adding or nivolumab + ipilimumab followed by nivolumab and chemo-radiation, safety will be monitored by a Bayesian stopping rule for the rate of treatment-related AEs leading to discontinuation greater than 30% (summarized baseline toxicity rate). For example, if 3 patients out of the first 6 or 4 out of the first 7 evaluable patients experience treatment-related AEs leading to discontinuation, accrual to the trial will be temporarily suspended and the principle investigator and study team will review the toxicity data and recommend either modification or termination of the trial.

Details
Condition Locally Advanced Pancreatic Cancer (LAPC)
Treatment SBRT, Gemcitabine, Ipilimumab, Nab-paclitaxel, Nivolumab
Clinical Study IdentifierNCT04247165
SponsorHerlev Hospital
Last Modified on8 August 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Signed informed consent
Subjects must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal subject care
Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study
Histological or cytological confirmation of locally advanced pancreatic carcinoma
No prior chemotherapy regimens received for PC
prior to entering this study
Age 18 years or older
Life expectancy greater than 6 months
ECOG/WHO Performance Status (PS) 0-1
All participants will be required to undergo mandatory pre- and on-treatment biopsies at acceptable clinical risk as judged by the investigator. An archival pre-treatment sample is acceptable
Patients must have normal organ and marrow function as defined below
Absolute neutrophil count (ANC) ≥ 1.5 x 10⁹/L
Platelet count ≥ 100 x 10⁹/L
Serum bilirubin ≤ 1.5 x upper limit of normal (ULN) (patients with Gilbert's Syndrome must have a total bilirubin ≤ 50 mmol/L)
AST/ALT ≤ 5 x ULN
Serum creatinine ≤ 1.5 x ULN or CrCl ≥ 40 mL/min (using the Cockcroft-Gault formula)
Women of child bearing potential (WOCBP) must use method(s) of contraception as
Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year (Appendix 3). The investigator shall review contraception methods and the time period that contraception must be followed. Men that are sexually active with WOCBP must follow instructions for birth control when the half-life of the investigational drug is greater than 24 hours, contraception should be continued for a period of 90 days plus the time required for the investigational drug to undergo five half-lives. The half-life of nivolumab is up to 25 days. Men who are sexually active with WOCBP must continue contraception for 31 weeks (90 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug. Women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile as well as azoospermic men do not require contraception
indicated in Appendix 3. For a teratogenic study drug and/or when there is
Subjects must have signed and dated a BIOPAC approved written informed consent form in accordance with regulatory and institutional guidelines
insufficient information to assess teratogenicity (preclinical studies have
not been done), a highly effective method(s) of contraception (failure rate of
less than 1% per year) is required. The individual methods of contraception
and duration should be determined in consultation with the investigator. WOCBP
must follow instructions for birth control when the half-life of the
investigational drug is greater than 24 hours, contraception should be
continued for a period of 30 days plus the time required for the
investigational drug to undergo five half-lives. The half-life of nivolumab
and ipilimumab is up to 25 days and 18 days, respectively. WOCBP should
therefore use an adequate method to avoid pregnancy for 23 weeks (30 days plus
the time required for nivolumab to undergo five half-lives) after the last
dose of investigational drug

Exclusion Criteria

Metastatic disease
Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results
Participants with active, known or suspected autoimmune disease. Participants with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll
Participants with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Patients should be excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
Allergies and adverse drug reaction
History of allergy to study drug components
History of severe hypersensitivity reaction to any monoclonal antibody
WOCBP who are pregnant or breastfeeding
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note